Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1991 Jan;63(1):71–74. doi: 10.1038/bjc.1991.15

Differential efficacy of flavone acetic against liver versus lung metastases in a human tumour xenograft.

G Pratesi 1, C Manzotti 1, M Tortoreto 1, R A Audisio 1, F Zunino 1
PMCID: PMC1971638  PMID: 1989668

Abstract

A human ovarian carcinoma, IGROV-1, was xenografted into different sites (i.p., s.c., i.v., and intrasplenically) in nude athymic female mice to investigate the pattern of antitumour efficacy of FAA and compare it to that of doxorubicin and cisplatin, two established cytotoxic drugs. Ascitic and lung-growing tumours totally failed to respond to FAA, whereas s.c. and liver-growing tumours were significantly growth inhibited. This pattern of activity differs from that achieved by the two conventional cytotoxic drugs, which were active against the IGROV-1 tumour growing in all of the tested sites. These studies indicate that cytotoxicity is not the major determinant of FAA antitumour efficacy even against human tumour xenografts. Moreover, the dramatic difference between the sensitivity of lung and liver tumour colonies demonstrates the great importance of the site of tumour growth for FAA efficacy.

Full text

PDF
71

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alley M. C., Scudiero D. A., Monks A., Hursey M. L., Czerwinski M. J., Fine D. L., Abbott B. J., Mayo J. G., Shoemaker R. H., Boyd M. R. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res. 1988 Feb 1;48(3):589–601. [PubMed] [Google Scholar]
  2. Bibby M. C., Double J. A., Loadman P. M., Duke C. V. Reduction of tumor blood flow by flavone acetic acid: a possible component of therapy. J Natl Cancer Inst. 1989 Feb 1;81(3):216–220. doi: 10.1093/jnci/81.3.216. [DOI] [PubMed] [Google Scholar]
  3. Bibby M. C., Double J. A., Phillips R. M., Loadman P. M. Factors involved in the anti-cancer activity of the investigational agents LM985 (flavone acetic acid ester) and LM975 (flavone acetic acid). Br J Cancer. 1987 Feb;55(2):159–163. doi: 10.1038/bjc.1987.32. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bibby M. C., Phillips R. M., Double J. A. Influence of site on the chemosensitivity of transplantable murine colon tumours to flavone acetic acid (LM975, NSC 347512). Cancer Chemother Pharmacol. 1989;24(2):87–94. doi: 10.1007/BF00263126. [DOI] [PubMed] [Google Scholar]
  5. Chabot G. G., Bissery M. C., Gouyette A. Flavone acetic acid (LM-975; NSC-347512) activation to cytotoxic species in vivo and in vitro. Cancer Chemother Pharmacol. 1989;24(5):273–276. doi: 10.1007/BF00304757. [DOI] [PubMed] [Google Scholar]
  6. Ching L. M., Baguley B. C. Induction of natural killer cell activity by the antitumour compound flavone acetic acid (NSC 347 512). Eur J Cancer Clin Oncol. 1987 Jul;23(7):1047–1050. doi: 10.1016/0277-5379(87)90357-9. [DOI] [PubMed] [Google Scholar]
  7. Corbett T. H., Bissery M. C., Wozniak A., Plowman J., Polin L., Tapazoglou E., Dieckman J., Valeriote F. Activity of flavone acetic acid (NSC-347512) against solid tumors of mice. Invest New Drugs. 1986;4(3):207–220. doi: 10.1007/BF00179586. [DOI] [PubMed] [Google Scholar]
  8. Cummings J., Double J. A., Bibby M. C., Farmer P., Evans S., Kerr D. J., Kaye S. B., Smyth J. F. Characterization of the major metabolites of flavone acetic acid and comparison of their disposition in humans and mice. Cancer Res. 1989 Jul 1;49(13):3587–3593. [PubMed] [Google Scholar]
  9. Damia G., Zanette M. L., Rossi C., Mandelli R., Ferrari A., D'Incalci M. Dose-dependent pharmacokinetics of flavone acetic acid in mice. Cancer Chemother Pharmacol. 1988;22(1):47–50. doi: 10.1007/BF00254180. [DOI] [PubMed] [Google Scholar]
  10. Evelhoch J. L., Bissery M. C., Chabot G. G., Simpson N. E., McCoy C. L., Heilbrun L. K., Corbett T. H. Flavone acetic acid (NSC 347512)-induced modulation of murine tumor physiology monitored by in vivo nuclear magnetic resonance spectroscopy. Cancer Res. 1988 Sep 1;48(17):4749–4755. [PubMed] [Google Scholar]
  11. Fekete E. A comparative morphological study of the mammary gland in a high and a low tumor strain of mice. Am J Pathol. 1938 Sep;14(5):557–578.5. [PMC free article] [PubMed] [Google Scholar]
  12. Finlay G. J., Smith G. P., Fray L. M., Baguley B. C. Effect of flavone acetic acid on Lewis lung carcinoma: evidence for an indirect effect. J Natl Cancer Inst. 1988 Apr 20;80(4):241–245. doi: 10.1093/jnci/80.4.241. [DOI] [PubMed] [Google Scholar]
  13. Fisher B., Wolmark N., Rockette H., Redmond C., Deutsch M., Wickerham D. L., Fisher E. R., Caplan R., Jones J., Lerner H. Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: results from NSABP protocol R-01. J Natl Cancer Inst. 1988 Mar 2;80(1):21–29. doi: 10.1093/jnci/80.1.21. [DOI] [PubMed] [Google Scholar]
  14. Giavazzi R., Garofalo A., Damia G., Garattini S., D'Incalci M. Response to flavone acetic acid (NSC 347512) of primary and metastatic human colorectal carcinoma xenografts. Br J Cancer. 1988 Mar;57(3):277–280. doi: 10.1038/bjc.1988.59. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Hornung R. L., Young H. A., Urba W. J., Wiltrout R. H. Immunomodulation of natural killer cell activity by flavone acetic acid: occurrence via induction of interferon alpha/beta. J Natl Cancer Inst. 1988 Oct 5;80(15):1226–1231. doi: 10.1093/jnci/80.15.1226. [DOI] [PubMed] [Google Scholar]
  16. Kerr D. J., Kaye S. B., Cassidy J., Bradley C., Rankin E. M., Adams L., Setanoians A., Young T., Forrest G., Soukop M. Phase I and pharmacokinetic study of flavone acetic acid. Cancer Res. 1987 Dec 15;47(24 Pt 1):6776–6781. [PubMed] [Google Scholar]
  17. Kerr D. J., Maughan T., Newlands E., Rustin G., Bleehen N. M., Lewis C., Kaye S. B. Phase II trials of flavone acetic acid in advanced malignant melanoma and colorectal carcinoma. Br J Cancer. 1989 Jul;60(1):104–106. doi: 10.1038/bjc.1989.230. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Lafreniere R., Rosenberg S. A. A novel approach to the generation and identification of experimental hepatic metastases in a murine model. J Natl Cancer Inst. 1986 Feb;76(2):309–322. [PubMed] [Google Scholar]
  19. Plowman J., Narayanan V. L., Dykes D., Szarvasi E., Briet P., Yoder O. C., Paull K. D. Flavone acetic acid: a novel agent with preclinical antitumor activity against colon adenocarcinoma 38 in mice. Cancer Treat Rep. 1986 May;70(5):631–635. [PubMed] [Google Scholar]
  20. Pratesi G., Manzotti C., Damia G., D'Incalci M. Response of chemically induced primary colon tumours of the mouse to flavone acetic acid (NSC 347 512). Br J Cancer. 1988 Aug;58(2):144–146. doi: 10.1038/bjc.1988.181. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Smith G. P., Calveley S. B., Smith M. J., Baguley B. C. Flavone acetic acid (NSC 347512) induces haemorrhagic necrosis of mouse colon 26 and 38 tumours. Eur J Cancer Clin Oncol. 1987 Aug;23(8):1209–1211. doi: 10.1016/0277-5379(87)90157-x. [DOI] [PubMed] [Google Scholar]
  22. Wiltrout R. H., Boyd M. R., Back T. C., Salup R. R., Arthur J. A., Hornung R. L. Flavone-8-acetic acid augments systemic natural killer cell activity and synergizes with IL-2 for treatment of murine renal cancer. J Immunol. 1988 May 1;140(9):3261–3265. [PubMed] [Google Scholar]
  23. Zaharko D. S., Grieshaber C. K., Plowman J., Cradock J. C. Therapeutic and pharmacokinetic relationships of flavone acetic acid: an agent with activity against solid tumors. Cancer Treat Rep. 1986 Dec;70(12):1415–1421. [PubMed] [Google Scholar]
  24. Zwi L. J., Baguley B. C., Gavin J. B., Wilson W. R. Blood flow failure as a major determinant in the antitumor action of flavone acetic acid. J Natl Cancer Inst. 1989 Jul 5;81(13):1005–1013. doi: 10.1093/jnci/81.13.1005. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES